Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nexalin Technology, Inc. - Common Stock (NQ:NXL)

1.936 -0.074 (-3.69%)
Streaming Delayed Price Updated: 9:36 AM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 22,659
Open 1.950
Bid (Size) 1.920 (1)
Ask (Size) 1.990 (4)
Prev. Close 2.010
Today's Range 1.936 - 1.960
52wk Range 0.5300 - 4.490
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Nexalin Technology Enrolls First Patients and Advances Toward Treatment in UCSD Clinical Trial
From Nexalin Technology, Inc.
Via GlobeNewswire
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on April 3
From Nexalin Technology, Inc.
Via GlobeNewswire

Performance

YTD
-39.7%
-39.7%
1 Month
-20.0%
-20.0%
3 Month
-39.7%
-39.7%
6 Month
+210.3%
+210.3%
1 Year
-32.5%
-32.5%

More News

Read More
Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESS Newswire
(NXL) - Analyzing Nexalin Technology's Short Interest
Via Benzinga
Nexalin Technology Receives Notice of Allowance from the USPTO for Patent Covering Deep Intracranial Frequency Stimulation (DIFS™) Technology for Opioid and Other Substance Use Disorders
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Announces Initiation of Patient Recruitment for UCSD’s TBI & PTSD Clinical Study Following IRB Approval
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Welcomes General Wesley Clark to Military & Government Advisory Board
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Announces UCSD IRB Approval for use of HALO™ Clarity in Clinical Trials for mTBI and PTSD Treatment
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Appointed as Industry Co-Chair of National TBI Registry Coalition
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin’s Breakthrough DIFS™ Neurostimulation Device Demonstrates Reduction in Blood Pressure while Enhancing Mental Health According to New Landmark Study
From Nexalin Technology, Inc.
Via GlobeNewswire
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session, Today, January 23
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology CEO Mark White Issues Letter to Shareholders Highlighting Recent Achievements and Outlook for 2025
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Completes Phase 1of its Innovative Virtual Clinic
From Nexalin Technology, Inc.
Via GlobeNewswire
New Peer-Reviewed Publication Validates Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Technology, Reinforcing Leadership in High-Growth Neuromodulation Market
From Nexalin Technology, Inc.
Via GlobeNewswire
Dow Jumps Over 400 Points; Monday.com Shares Fall After Q3 Results
Via Benzinga
Topics Stocks
Exposures US Equities
Nexalin Technology CEO Provides Letter to Shareholders
From Nexalin Technology, Inc.
Via GlobeNewswire
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on November 5th
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements
From Nexalin Technology, Inc.
Via GlobeNewswire
LOBO EV and Nexalin Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESSWIRE
Nexalin Technology Announces Landmark Study on Alzheimer's Disease and Deep Intracranial Frequency Stimulation Published in Journal of Alzheimer's Disease
From Nexalin Technology, Inc.
Via GlobeNewswire
EXCLUSIVE: Nexalin Technology Says New Data Confirms Implantable Device Improves Cognitive Function, Restores Brain Activity in Alzheimer's Patients
Via Benzinga
NASDAQ Stocks Under $1 to Watch in October 2024: LGCB, KAVL, NXL, NXU, FAMI
Via AB Newswire
Topics Economy Electric Vehicles
Exposures Electric Vehicles Supply Chain
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESSWIRE

Frequently Asked Questions

Is Nexalin Technology, Inc. - Common Stock publicly traded?
Yes, Nexalin Technology, Inc. - Common Stock is publicly traded.
What exchange does Nexalin Technology, Inc. - Common Stock trade on?
Nexalin Technology, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Nexalin Technology, Inc. - Common Stock?
The ticker symbol for Nexalin Technology, Inc. - Common Stock is NXL on the Nasdaq Stock Market
What is the current price of Nexalin Technology, Inc. - Common Stock?
The current price of Nexalin Technology, Inc. - Common Stock is 1.936
When was Nexalin Technology, Inc. - Common Stock last traded?
The last trade of Nexalin Technology, Inc. - Common Stock was at 04/03/25 09:36 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.